Subsequent to the 2025 year end, Burcon made continued significant progress in its strategic initiatives. The Company successfully scaled up commercial production of its pea protein isolate, marking a pivotal milestone in its go-to-market strategy. This scale up was accomplished at the Company’s Galesburg facility and took less than 90 days. The truncated timeframe enables Burcon to meet customer demand and unlock revenue opportunities. One notable revenue opportunity is a $6.8M multi-year production agreement that BU entered into subsequent to year end. This facility was in part made possible by the Company’s partnership with ProMan, detailed below. The pea protein market is expected to have a TAM of approximately US$215M to US$392M.